PMID- 29845475
OWN - NLM
STAT- MEDLINE
DCOM- 20190306
LR  - 20220330
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 171
IP  - 2
DP  - 2018 Sep
TI  - High expression of long non-coding RNA MALAT1 in breast cancer is associated with 
      poor relapse-free survival.
PG  - 261-271
LID - 10.1007/s10549-018-4839-2 [doi]
AB  - PURPOSE: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been 
      identified as a prognostic marker for the metastasis of early-stage non-small 
      cell lung cancer (NSCLCs). We studied MALAT1 expression in breast cancer in 
      relation to disease features and patient survival. METHODS: Quantitative reverse 
      transcriptase-polymerase chain reaction (qRT-PCR) was used to measure MALAT1 
      expression in tumor samples of 509 breast cancer patients. Hazards ratios (HRs) 
      and 95% confidence intervals (CIs) were calculated to assess the association 
      between MALAT1 expression and breast cancer survival using the Cox proportional 
      hazards regression model, and the analysis was adjusted for age at surgery, tumor 
      grade, disease stage, and hormone receptor status. Meta-analysis of multiple 
      microarray datasets from online databases and our own study was performed to 
      evaluate the association of MALAT1 with breast cancer survival. RESULTS: Patients 
      with low-grade or ER-positive tumors had higher expression of MALAT1 compared to 
      those with high-grade (p = 0.013) or ER-negative (p = 0.0002) tumors. Patients 
      with PR-positive tumors also had higher MALAT1 expression than those with 
      PR-negative tumors (p < 0.0001). In patients with positive hormone receptors or 
      low tumor grade, tumors with high MALAT1 expression were more likely to recur. 
      Survival analysis showed that patients with high expression of MALAT1 had a 
      twofold increase in risk of relapse (p = 0.0083) compared to those with low 
      expression. This association remained significant after adjustment for age at 
      surgery, disease stage, tumor grade, and hormone receptor status. Meta-analysis 
      showed that high MALAT1 expression was associated with poor relapse-free survival 
      in patients with hormone receptor-positive tumors (HR 1.44, 95% CI 1.08-1.92). 
      CONCLUSIONS: High expression of lncRNA MALAT1 is associated with breast cancer 
      relapse and may play a role in tumor progression.
FAU - Wang, Zhanwei
AU  - Wang Z
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo 
      Street, Honolulu, HI, 96813, USA.
FAU - Katsaros, Dionyssios
AU  - Katsaros D
AD  - Department of Surgical Sciences, Gynecology, AOU Citta della Salute, University 
      of Torino School of Medicine, Turin, Italy.
FAU - Biglia, Nicoletta
AU  - Biglia N
AD  - Department of Surgical Sciences, Division of Obstetrics and Gynecology, 
      University of Torino School of Medicine, Mauriziano Hospital, Turin, Italy.
FAU - Shen, Yi
AU  - Shen Y
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo 
      Street, Honolulu, HI, 96813, USA.
FAU - Fu, Yuanyuan
AU  - Fu Y
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo 
      Street, Honolulu, HI, 96813, USA.
AD  - Department of Molecular Biosciences & Bioengineering, University of Hawaii at 
      Manoa, Honolulu, HI, USA.
FAU - Loo, Lenora W M
AU  - Loo LWM
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo 
      Street, Honolulu, HI, 96813, USA.
FAU - Jia, Wei
AU  - Jia W
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo 
      Street, Honolulu, HI, 96813, USA.
FAU - Obata, Yuki
AU  - Obata Y
AD  - College of Pharmacy, Kinjo Gakuin University, Nagoya, Aichi, Japan.
FAU - Yu, Herbert
AU  - Yu H
AUID- ORCID: 0000-0003-3950-4815
AD  - Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Ilalo 
      Street, Honolulu, HI, 96813, USA. hyu@cc.hawaii.edu.
LA  - eng
GR  - P30 CA071789/CA/NCI NIH HHS/United States
GR  - R01 CA138698/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180529
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MALAT1 long non-coding RNA, human)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Biomarkers, Tumor
MH  - Breast Neoplasms/*genetics/metabolism/*mortality/pathology
MH  - Cell Line, Tumor
MH  - CpG Islands
MH  - DNA Methylation
MH  - Disease Progression
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Odds Ratio
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - RNA, Long Noncoding/*genetics
MH  - Receptors, Estrogen/metabolism
PMC - PMC6488226
MID - NIHMS1024789
OTO - NOTNLM
OT  - Breast cancer
OT  - Estrogen receptor
OT  - MALAT1
OT  - Meta-analysis
OT  - Survival
COIS- Disclosure of potential conflicts of interest None
EDAT- 2018/05/31 06:00
MHDA- 2019/03/07 06:00
PMCR- 2019/04/29
CRDT- 2018/05/31 06:00
PHST- 2018/04/22 00:00 [received]
PHST- 2018/05/25 00:00 [accepted]
PHST- 2018/05/31 06:00 [pubmed]
PHST- 2019/03/07 06:00 [medline]
PHST- 2018/05/31 06:00 [entrez]
PHST- 2019/04/29 00:00 [pmc-release]
AID - 10.1007/s10549-018-4839-2 [pii]
AID - 10.1007/s10549-018-4839-2 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2018 Sep;171(2):261-271. doi: 10.1007/s10549-018-4839-2. 
      Epub 2018 May 29.